Depuy Mitek, Inc.

Depuy Synthes Products, Inc.

Advanced Technologies and Regenerative Medicine, LLC

Psivida Us, Inc.

Johnson & Johnson Regenerative Therapeutics, LLC

Medos International Sarl

Eyepoint Pharmaceuticals Us, Inc.

Advanced Technogies and Regenerative Medicine, LLC

Control Delivery Systems, Inc.

Dongling Su

Julia Hwang

Venkata R Garigapati

Julius Lopez

Benjamin A Byers

Paul Ashton

Brooks J Story

Jianbing Chen

Rehan Khanzada

Steven J Sawamura

Hong Guo

Uri Herzberg

William R Parrish

Donna Schulz Torres

Scott A Wadsworth

Ben Byers

Peter Francis Daniel

Asok C Sen

Peter Daniel

Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluronic acid ('HA'), in combination with a lyophilized second component that is effective to at least temporarily reduce the viscosity of the HA. In an exemplary embodiment, the second component is one or more glycosaminoglycans ('GAG'), such as chondroitin sulfate (&#x201c;CS&#x201d;), including CS4 and/or CS6, dermatan sulfate, heparin, heparan sulfate, and keratan sulfate. The composition can optionally include other joint supplements, such as glucosamine (&#x201c;GlcN&#x201d;).

Compositions and methods for treating joints

Compositions and methods are disclosed for the treatment of osteoarthritis. The compositions comprising combinations of hyaluronic acid, glucosamine, and chondroitin sulfate, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.

The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery.

Bioerodible sustained release drug delivery systems

The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.

In situ gelling drug delivery system

Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.

Compositions for treating joints comprising bone morphogenetic protein and hyaluronic acid

Methods for forming compositions for treating joints comprising bone morphogenetic protein and hyaluronic acid

The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants.

Protein stabilization formulations

Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluronic acid ('HA'), in combination with at least one stabilizer. The composition can include a stabilizer that increases the stability and shelf-life of the HA. In another embodiment, the compositions and methods can also include an additional component, such as one or more glycosaminoglycans ('GAG') or GAG precursors. Examples of GAGs or GAG precursors can include chondroitin sulfate (&#x201c;CS&#x201d;), dermatan sulfate, heparin, heparan sulfate, keratan sulfate, and glucosamine (&#x201c;GlcN&#x201d;).

Compositions and methods for stabilized polysaccharide formulations

Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluraonic acid ('HA'), in combination with a lyophilized second component that is effective to at least temporarily reduce the viscosity of the HA. In an exemplary embodiment, the second component is one or more glycosaminoglycans ('GAG'), such as chondroitin sulfate (&#x201c;CS&#x201d;), including CS4 and/or CS6, dermatan sulfate, heparin, heparan sulfate, and keratan sulfate. The composition can optionally include other joint supplements, such as glucosamine (&#x201c;GlcN&#x201d;).

Improved compositions and methods are provided for stabilizing a solution of bone morphogenetic protein. The compositions comprise an aqueous solution of GDF-5 and a biocompatible acid, such as hydrochloric, acetic, phosphoric, or trifluoroacetic acid, wherein the solution has a pH of from about 3.0 to about 3.6, thereby providing for improved stability of the GDF-5 protein during handling and prolonged storage at reduced temperatures.

Stable composition of GDF-5 and method of storage

Growing community of inventors

Franklin, MA, United States of America

Dongling Su